Home
About Us
Company Profile Development History Corporate Culture

     Aurovitas Pharma Taizhou Co., Ltd. was established in China Medical City in January 2018, with a registered capital of USD 90.8 million. Aurovitas is primarily engaged in the production and R&D of OSD. The plant covers an area of approximately 97 mu, including production and auxiliary facilities such as quality block and OSD production workshop.


News
Information Feedback
Contact Us
EN / 中

Company Profile

Aurovitas Pharma Taizhou Co., Ltd was registered and established in China Medical City.

     Aurovitas Pharma Taizhou Co., Ltd. was established in China Medical City in January 2018, with a registered capital of USD 90.8 million. As a wholly-owned subsidiary of Aurobindo Pharma, Aurovitas is primarily engaged in the production and R&D of OSD. The plant covers an area of approximately 97 mu, including production and auxiliary facilities such as quality block and OSD production workshop.


Explore More Content

Collection of adverse drug reactions

Improving the level of rational clinical medication to ensure the safety and effectiveness of public medication

Regular Inspection

Regularly inspect our equipment and instruments to ensure they meet the requirements

Equipment and Instruments

We use the best instruments and programs in the world for testing

Join Us

Our company's employees have extensive experience in EU and Chinese FDA audits

Business Area

 Aurovitas is primarily engaged in the production and R&D of OSD.